Tested extra radiation to the tumor area in HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study follows people with HER2-positive invasive breast cancer to see how adding radiation to the tumor bed may affect outcomes. It may be most relevant if you are scheduled for breast radiation and have not had radiation to the same side before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re female and at least 19 years old
- Your breast cancer has been confirmed as HER2-positive and invasive (not just a pre-cancer)
- Your usual daily activity is fairly normal (doctor rates you as 0–2)
- You can read and sign a consent form to join the study
- You do not have ductal carcinoma in situ (DCIS) only
- You have not had radiation therapy to your breast on the same side (ipsilateral) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether definitive radiation therapy can effectively treat breast cancer that cannot be surgically removed. It may be an option for people whose cancer is inoperable or who choose not to have surgery.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests giving a focused, higher dose of radiation to the lymph nodes above the collarbone after breast cancer treatment. It is for patients whose cancer did not fully disappear from those nodes after pre-surgery chemotherapy, to see if extra radiation can help prevent recurrence.
This study tests a combination of an immunotherapy drug (toripalimab) and a targeted type of radiation called SBRT for breast cancer that didn't shrink with standard chemo. It aims to see if this combination can help your body fight the cancer better.
This trial tests a short, more intense radiation schedule for women with certain breast cancer types or who are under 40. It aims to reduce treatment time while still targeting the whole breast and any high-risk areas.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.